BrainStorm Announces Redemption of Outstanding Warrants for Cash

BrainStorm Announces Redemption of Outstanding Warrants for Cash 
NEW YORK, NY and PETACH TIKVAH, ISRAEL -- (Marketwired) -- 05/29/14
--  BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI) announced today
that it has entered into agreements with holders of warrants
originally issued in the Company's August 16, 2013 public offering,
to repurchase outstanding warrants to purchase an aggregate of
approximately five (5) million shares of Company Common Stock,
$0.00005 par value, and for the payment to the holders of an
aggregate of approximately $600,000. The holder of each repurchased
warrant received from the Company a cash payment equal to $0.12 per
share of Common Stock issuable pursuant to such warrant. All
repurchased warrants were cancelled and are of no further force and
effect. The purpose of the repurchase is to facilitate the Company's
plans to uplist its stock to a national securities exchange such as
About BrainStorm Cell Therapeutics, Inc.
 BrainStorm Cell
Therapeutics Inc. is a biotechnology company engaged in the
development of first-of-its-kind adult stem cell therapies derived
from autologous bone marrow cells for the treatment of
neurodegenerative diseases. The Company holds the rights to develop
and commercialize its NurOwn technology through an exclusive,
worldwide licensing agreement with Ramot, the technology transfer
company of Tel Aviv University. For more information, visit the
Company's website at  
Safe Harbor Statement
 Statements in this announcement other than
historical data and information constitute "forward-looking
statements" and involve risks and uncertainties that could cause
BrainStorm Cell Therapeutics Inc.'s actual results to differ
materially from those stated or implied by such forward-looking
statements. Terms and phrases such as "may", "should", "would",
"could", "will", "expect", "likely", "believe", "plan", "estimate",
"predict", "potential", and similar terms and phrases are intended to
identify these forward-looking statements. The potential risks and
uncertainties include, without limitation, risks associated with
BrainStorm's limited operating history, history of losses; minimal
working capital, dependence on its license to Ramot's technology;
ability to adequately protect the technology; dependence on key
executives and on its scientific consultants; ability to obtain
required regulatory approvals; and other factors detailed in
BrainStorm's annual report on Form 10-K and quarterly reports on Form
10-Q available at These factors should be
considered carefully, and readers should not place undue reliance on
BrainStorm's forward-looking statements. The forward-looking
statements contained in this press release are based on the beliefs,
expectations and opinions of management as of the date of this press
release. We do not assume any obligation to update forward-looking
statements to reflect actual results or assumptions if circumstances
or management's beliefs, expectations or opinions should change,
unless otherwise required by law. Although we believe that the
expectations reflected in the forward-looking statements are
reasonable, we cannot guarantee future results, levels of activity,
performance or achievements. 
BrainStorm Cell Therapeutics Inc. 
Mr. Chaim Lebovits
Phone: +972-3-9236384  
US Investor Contact
LifeSci Advisors, LLC
Michael Rice
Phone: 646-597-6979 
Press spacebar to pause and continue. Press esc to stop.